Israeli-American biotech Chiasma has raised $70 million as it moves toward FDA approval with a treatment for the hormone disorder acromegaly. With the money, Chiasma plans to file an FDA application for oral octreotide, a treatment for the rare disorder. The company expects to submit the drug next quarter and,...

Submissions are now open for the EUROPEAN BIOTECHNICA AWARD. The coveted award will go to a European company that has introduced a disruptive technology in the field of biotechnology or the life sciences and has demonstrably shepherded it through to successful commercialization. The EUROPEAN BIOTECHNICA AWARD is offered by Deutsche...

Gamida Cell, a developer of cell therapy technologies and products for transplantation and adaptive immune therapy, announced that orphan drug designation has been granted by the FDA for its investigational medicinal product NiCord. The drug is used for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin...

Ramat Gan-based EarlySense, which provides solutions for contact-free patient monitoring, announced today that it has completed a $20 million financing round, led by Samsung Ventures with an investment of $10 million. Existing investors whose participation was also substantial include Pitango Venture Capital, Welch Allyn, JK&B, Proseed and Noaber. “We are...